Agenus and Ludwig Sign Agreement for Further Development of Novel Immunotherapies
Thursday, December 11, 2014 - 10:30
in Health & Medicine
Ludwig Cancer Research announced today an agreement with Agenus that grants the Lexington, MA-based biotechnology company exclusive license to further develop and commercialize antibodies against three molecules--GITR, OX40 and TIM3--that play distinct and important roles in immune cell regulation and have been identified and assessed as drug targets by Ludwig researchers. Antibodies that activate GITR and OX40 or block TIM-3 have been shown to induce potent anti-tumor immune responses in preclinical studies and could prove to be important anti-cancer immunotherapies.